title: Endocrine response to a single injection of goserelin 3.6 mg or leuprolide 3.75 mg in men with prostate cancer.
abstract: Hormonal responses were assessed in men with prostate cancer (T2-4, Nx, Mx) who were randomized to receive either a single injection of goserelin 3.6 mg or leuprolide 3.75 mg. Testosterone increased over the first week, with a significantly higher mean rate of change of total testosterone (day 3) and free testosterone (days 3 and 7) with leuprolide. Following the initial rise in luteinizing hormone (LH), the rate of decrease in LH levels was significantly greater with goserelin by day 28. There are significant differences in endocrine response to goserelin and leuprolide in the 4 weeks following administration.
authors: Department of Urology, Nara Medical University, Nara, Japan.
authors: N
authors: N
authors: Tanaka
authors: K
authors: K
authors: Fujimoto
authors: Y
authors: Y
authors: Hirao
authors: K
authors: K
authors: Shimizu
authors: S
authors: S
authors: Tsujimoto
authors: S
authors: S
authors: Samma
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D017273:Goserelin / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007279:Injections, Subcutaneous; D007700:Kinetics; D016729:Leuprolide / Q000008:administration & dosage / Q000494:pharmacology*; D007986:Luteinizing Hormone / Q000378:metabolism; D008297:Male; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D013739:Testosterone / Q000378:metabolism*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin; D013739:Testosterone; D007986:Luteinizing Hormone; D017430:Prostate-Specific Antigen; D016729:Leuprolide